What top creators are saying about Eli Lilly and Company(LLY)— Page 4

Discussed in relation to its product Zyprexa, which was linked to a side effect of 'sudden death,' illustrating that massive profits can outweigh financial penalties for misconduct.

Cited as an example of a non-tech stock performing strongly ('crushing it'), demonstrating a healthy market rotation that is considered bullish for the overall market.

Identified as a healthcare/defensive stock that is seeing inflows as institutional investors rotate out of technology.

The stock is performing well, which is seen as a healthy sign of market broadening beyond the technology sector.

The company is described as 'clearly winning' the highly lucrative obesity drug war, with its stock rising on the back of its main competitor's negative report.

The speaker is highly optimistic about the company's new weight-loss drug, describing the data as 'powerful' and its potential combination with GLP-1s as 'revolutionary'.

Mentioned as a market leader in the booming weight-loss drug sector, a market projected to grow significantly by 2030.

Reportedly close to a deal with the White House for Medicare coverage of its obesity drugs, which would be a 'significant bullish catalyst' by opening up a massive new market.

Described as 'hands down... winning the weight loss drug wars,' reflected in a massive beat on both earnings and revenue, confirming its dominant position in the market.

Stock fell alongside other GLP-1 drug makers due to potential government-mandated price controls, which presents a significant risk to profitability despite the massive potential market for its weight-loss drugs.

The stock was down along with others in the GLP-1 space following comments from Donald Trump.

Mentioned as an example of a major company involved in the 'revolving door' with regulatory agencies like the FDA, creating significant conflicts of interest and a risky investment environment.

The stock carries significant political and headline risk due to its successful GLP-1 franchise, making it sensitive to any rhetoric about drug price controls, which could cause volatility.

Identified as a company that could see a dramatic reduction in revenue due to its weight-loss drugs if a policy forcing lower drug prices were implemented.

Mentioned as a 'high-flyer' in the healthcare sector, which is excluded from the potential value play in the broader, more defensive healthcare sector during a market rotation.

Strong qualitative, demand-side bull case based on the massive scale and rapid adoption of its GLP-1 drugs (Zepbound, Mounjaro), with potential for expanded use in treating addiction and other compulsive behaviors.

Viewed as outperforming competitor Novo Nordisk in the weight-loss drug space. Also mentioned as a potential acquirer of Abivax.

The company has a very bullish outlook due to exceptional revenue growth (38-40%) driven by key products Mounjaro and Zepbound, aggressive manufacturing expansion, and a robust R&D pipeline.

The company is experiencing massive growth driven by its GLP-1 drug Mounjaro, with a robust pipeline and strong capital allocation strategy for R&D and expansion. Its market is expected to grow with new drug applications for mental health and addiction.

As a primary company dominating the GLP-1 market, the ongoing bull thesis is validated by the transformative impact of its drugs, with the market's potential still in its early stages.

The partnership with Google's Isomorphic Labs for AI-driven drug discovery is a key catalyst that could significantly accelerate its R&D pipeline. The first drug candidates from this collaboration are expected to enter the preclinical phase in 2025.

The discussion validates the transformational impact of GLP-1 drugs, creating a strong tailwind for the pharmaceutical companies leading this space, as the underlying societal health issues driving demand are deeply entrenched.

As a key competitor in the GLP-1 drug market, the company benefits from the massive market penetration of these drugs, which is considered a 'highly bullish indicator' for producers.

Faces a strongly bearish outlook from an ethical and regulatory risk standpoint due to a $2 billion lawsuit, a lawsuit from the state of Texas, and accusations of destroying records and lobbying to restrict competition. A key risk/opportunity is its attempt to reclassify drugs as 'biologics' to secure a 12-year monopoly.

While benefiting from a major tailwind of high demand for its GLP-1 drugs, the company's profitability is mediated by powerful PBMs. Any legislation that curbs the power of PBMs could be a significant positive catalyst.

Carries a very high valuation (36x 2025 earnings) because the market is pricing in long-term earnings potential from its incredible drug pipeline, especially weight-loss drugs Mounjaro and Zepbound.

Mentioned as a source of Fear, Uncertainty, and Doubt (FUD) for Hims & Hers due to the threat of lawsuits over compounded GLP-1s.

The development of an effective oral weight-loss pill (Orphaglipron) is seen as a game-changer that could significantly expand the market and give it a strong competitive advantage over Novo Nordisk.

Owns the intellectual property for life-changing drugs with unprecedented global demand, but faces significant competition from a parallel market that emerged due to their failure to meet initial supply. Long-term value depends on their ability to scale production and fend off lower-priced competition.

Multiple insiders, including the CFO, are 'buying the dip,' which is a bullish signal indicating internal confidence that the company's fundamentals are strong and the stock will recover.

Six different insiders bought a combined $4 million in stock after a price drop following disappointing drug trial news, signaling a strong belief that the market overreacted and the stock is undervalued.

Mentioned as a partner to LifeMD, supplying branded medications. This partnership allows LifeMD to avoid the legal risks associated with compounding drugs that affect its competitors.

Five insiders, including the CEO, purchased a combined $2.89 million in stock after a 20% price drop, signaling immense confidence that the stock is undervalued. The insiders have a proven track record of successful trades.

The speaker believes the days of 'massive growth may be over' for the GLP-1 drug class. While the market may still grow 5-10% annually, the explosive growth phase is considered finished, representing a more cautious outlook.

Stock fell 14% despite great earnings and raised guidance, due to disappointing test data for a future daily obesity pill that did not meet high investor expectations.

Mentioned as a primary competitor gaining market share from Novo Nordisk due to its drugs having lower perceived side effects. The market is seen as large enough for both companies to succeed.

The company's weight loss drug, Mounjaro, is successfully taking market share from Novo Nordisk's Wegovy, indicating strong competitive positioning.

Showed resilience and posted gains during a broad market sell-off, acting as a defensive healthcare stock.

Considered a more conservative investment in the AI drug discovery theme, leveraging the technology through a billion-dollar partnership with Alphabet's Isomorphic Labs.

Viewed as the clear winner and market leader in the GLP-1 space, with its drug Zepbound capturing 60% of new US prescriptions and being preferred by doctors, indicating a very strong competitive position and momentum.

Viewed as the clear winner in the obesity drug market, with its drugs Mounjaro and Zepbound 'crushing' the competition from Novo Nordisk.

The speaker believes that any major issues for its competitor, Novo Nordisk (NVO), would also be bearish for Eli Lilly.

Strongly preferred over Novo Nordisk for exposure to the GLP-1 market due to its superior current drug (Trizepatide) and a more promising drug in its pipeline (Retatrutide).

Shares were pulled down by negative news from competitor Novo Nordisk, suggesting broader market concerns about competition in the GLP-1 drug sector.

Planning a $27 billion investment in U.S. operations, reinforcing the view that established brand-name drug makers are well-positioned to absorb onshoring costs.

The speaker is bullish due to Lilly's leadership in the high-growth GLP-1 market and its 'Lilly direct' program, which is seen as a key strategic advantage.

The company faces significant political and regulatory risk due to government-mandated price caps on insulin. This pressure has led to price slashing, which can curtail long-term profitability and is a key risk factor for investors.

The speaker's preferred pure-play investment in the GLP-1 weight-loss drug space, favored over Novo Nordisk (NVO) due to the belief that its drugs are superior.

Mentioned as a 'Big Pharma' competitor to Hims & Hers, representing a major competitive threat in the lucrative weight-loss drug market.

A major competitor to Novo Nordisk whose weight-loss drugs (Zepbound, Mounjaro) are reportedly gaining significant market share and seeing prescription numbers grow much faster.